Oncology Medical News about colon cancers

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Clinical implications of microsatellite instability in sporadic colon cancers
Current Opinion in Oncology, 06/18/09

Sinicrope FA et al. - IN a study to review data demonstrating the prognostic and predictive impact of microsatellite instability (MSI) in human colon carcinomas, it was concluded that MSI is a molecular marker that can provide valuable prognostic and predictive information in colon cancer pts. In the appropriate clinical setting, MSI data can be used in clinical decision-making. Favorable outcome of stage II colon cancers with MSI indicates that such pts should not receive adjuvant chemotherapy.

Methods

MSI is a molecular marker of defective DNA mismatch repair that is detected in approximately 15% of sporadic colon cancers.
Most, but not all retrospective studies, have shown that colon cancers with MSI have better stage-adjusted survival rates vs non-MSI tumors.
Analyses of colon cancers from participants in randomized adjuvant therapy trials have suggested that MSI tumors do not benefit from treatment with 5-fluorouracil.

Results